Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,343 | 202 | 1,110 |
| Samples | 554 | 109 | 435 |
| Peptides | 449 | 71 | 383 |
Function
RAB11FIP1 · RAB11 family interacting protein 1
This gene encodes one of the Rab11-family interacting proteins (Rab11-FIPs), which play a role in the Rab-11 mediated recycling of vesicles. The encoded protein may be involved in endocytic sorting, trafficking of proteins including integrin subunits and epidermal growth factor receptor (EGFR), and transport between the recycling endosome and the trans-Golgi network. Alternative splicing results in multiple transcript variants. A pseudogene is described on the X chromosome. [provided by RefSeq, Dec 2013].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 427 amino-acid changes on canonical ENST00000330843 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RAB11FIP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RAB11FIP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 24/612 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Melanoma | 9/210 4% | 59/1899 3% |
| Other Solid Cancers | 2/94 2% | 34/1515 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 22/1390 2% |
| Colorectal Carcinoma | 5/143 4% | 62/3239 2% |
| Bladder Carcinoma | 0/58 0% | 20/956 2% |
| Neuroendocrine Tumour | 9/154 6% | 5/577 1% |
| Cervical Carcinoma | 0/35 0% | 8/422 2% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 10/810 1% |
| Gastric Carcinoma | 2/74 3% | 26/1809 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 27/2550 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Ewings Sarcoma | 0/63 0% | 3/262 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Head and Neck Carcinoma | 3/85 4% | 12/1574 1% |
| Medulloblastoma | 0/0 0% | 4/450 1% |
| Glioma | 1/52 2% | 18/2127 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Breast Carcinoma | 7/144 5% | 19/3264 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Other Sarcomas | 0/69 0% | 5/699 1% |
| Ovarian Carcinoma | 0/109 0% | 7/998 1% |
| Hepatocellular Carcinoma | 4/46 9% | 10/2210 0% |
Mutation Distribution
Where RAB11FIP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in RAB11FIP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,343 mutations in RAB11FIP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|